Investment
Features
FeesSafety
Academy
More
Pluang+

Compare iShares MSCI United Kingdom (FTSE) (EWU) vs 10X Genomics Inc (TXG) Price & Performance

iShares MSCI United Kingdom (FTSE)Trade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

iShares MSCI United Kingdom (FTSE) vs 10X Genomics Inc — how do they compare? iShares MSCI United Kingdom (FTSE) trades at $46.23 (market cap $3.62B), while 10X Genomics Inc trades at $78.75 (market cap $10.07B). The key difference: 10X Genomics Inc is far larger — about 2.8× iShares MSCI United Kingdom (FTSE)'s market cap, and 10X Genomics Inc is trading nearer its 52-week high, iShares MSCI United Kingdom (FTSE) nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI United Kingdom (FTSE) for 46 Days and 10X Genomics Inc for 92 Days on average.

EWUTXG
Market Cap
$3.62B$10.07B
Volume
923,8965,657,286
Sector
Broad Market / FactorHealth
52-Week High
$49.39$97.74
52-Week Low
$41.34$11.48
Typical Hold Time
46 Days92 Days
Enterprise Value
—$9.59B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

iShares MSCI United Kingdom (FTSE)

EWU, the iShares MSCI United Kingdom ETF, is trading at $45.93, down 0.95% amid broader market pressures. Technical indicators show a bearish trend with moving averages signaling sell pressure, though RSI levels suggest potential oversold conditions. The fund faces headwinds from UK economic concerns including rising gilt yields and inflation pressures, while recent government housing initiatives provide some sector-specific support.

The outlook remains cautious as UK economic vulnerabilities and rising borrowing costs weigh on sentiment. Investment opportunity exists for long-term investors seeking UK exposure at discounted levels, though near-term risks include persistent inflation and political uncertainty surrounding the upcoming budget announcement.

10X Genomics Inc

10x Genomics (TXG) trades at $76.10, down 5.65% on the day, as technical indicators signal bearish momentum with the stock below key resistance levels. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive operating cash flow of $136M in 2025, though it remains unprofitable with a -12.18% net margin. Recent developments include the launch of Atera spatial biology platform shipments and a patent victory against Parse Biosciences.

TXG presents a mixed investment case with strong product innovation and improving financial trends offset by high valuation metrics and persistent losses. The stock's risk/reward appears balanced near analyst consensus targets, requiring successful execution on Atera commercialization and path to profitability to justify current multiples.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

EWU

No sentiment data available yet.

TXG
4% Buy96% Sell
Avg holding period · 92 Days

Top news

Latest headlines on both assets

About iShares MSCI United Kingdom (FTSE)

EWU is a country-specific ETF that tracks the performance of the United Kingdom equity market. It provides exposure to large and mid-sized UK companies, with significant weightings in financials, energy, and healthcare, including Shell, AstraZeneca, and HSBC.

Read more on EWU →

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG →